A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients with Metastatic Colorectal Cancer Harboring FGFR Alterations

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations »